BioMarin Pharma (BMRN) Tops Q3 EPS by 15c, Offers Guidance
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $58.99 +2.02%
EPS Growth %: -34.0%
Financial Fact:
NET INCOME (LOSS) PER SHARE, DILUTED: -0.26
Today's EPS Names:
CRMT, More
EPS Growth %: -34.0%
Financial Fact:
NET INCOME (LOSS) PER SHARE, DILUTED: -0.26
Today's EPS Names:
CRMT, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q3 EPS of ($0.07), $0.15 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $391.7 million versus the consensus estimate of $367.09 million.
GUIDANCE:
BioMarin Pharma sees FY2018 revenue of $1.47-1.53 billion, versus the consensus of $1.51 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump said he was unaware of his earnings from crypto
- Franklin Covey (FC) Misses Q3 EPS by 2c, lowers Guidance
- Lockheed Martin frontrunner for $3.5B Ultra Maritime deal, sources say - FT
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
